跳至主要内容
临床试验/NCT04057768
NCT04057768已完成不适用

Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles

Venus Concept2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2019年8月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Venus Concept
入组人数
10
试验地点
2
主要终点
Overall Wrinkle Improvement Assessed by the Fitzpatrick Wrinkle and Elastosis Scale (FWES) at 12 Weeks Post-Final Treatment

研究概览

简要总结

The objective of this clinical study is to evaluate the efficacy of fractional RF for the treatment and reduction of acne scarring or facial wrinkles.

详细描述

Prospective, single centre, evaluator-blind, split face study of the efficacy of fractional radiofrequency (RF) for the treatment and reduction of acne scarring and facial wrinkles. The study will evaluate the progress of 15 subjects requesting treatment of scarring or facial wrinkles. The study will involve three treatments on both sides of the face with 3-5 week intervals between each treatment. Subjects will be followed at 6 and 12 weeks after their last treatment. Analysis will be performed on all subjects who receive at least one treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy, male or female subjects over 21 years of age who are seeking treatment and reduction of their acne scarring or wrinkles.
  • Able to read, understand and voluntarily provide written Informed Consent.
  • Able and willing to comply with the treatment/follow-up schedule and requirements.
  • Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study and have a negative Urine Pregnancy test at baseline.

排除标准

  • Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant).
  • Subjects with any implantable metal device in the treatment area
  • Permanent implant in the treated area, such as metal plates and screws (excluding dental implants), or an injected chemical substance.
  • Current or history of any kind of cancer, or dysplastic nevi
  • Severe concurrent conditions, such as cardiac disorders.
  • Pregnancy or intending to become pregnant during the study and nursing.
  • Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications.
  • History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only following a prophylactic regime.
  • Poorly controlled endocrine disorders, such as diabetes.
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
  • History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin.
  • History of bleeding coagulopathies, or use of anticoagulants (excluding daily aspirin).
  • Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last three months, if face is treated.
  • Use of isotretinoin (Accutane®) or other systemic retinoids within six months prior to treatment or as per investigators discretion.
  • Any surgical procedure in the treatment area within the last six months or before complete healing.
  • Treating over tattoo or permanent makeup.
  • Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.

结局指标

主要结局

Overall Wrinkle Improvement Assessed by the Fitzpatrick Wrinkle and Elastosis Scale (FWES) at 12 Weeks Post-Final Treatment

时间窗: 12 Weeks Post-Final Treatment

Evaluate the efficacy of overall facial wrinkles improvement assessed live by the Investigator and a subject assessment of facial appearance including the Fitzpatrick Wrinkle and Elastosis Scale (FWES). The FWES is a 9 point scale. Three independent evaluators evaluated before and after photographs and graded them for change. Possible responses were: a score of 1 - 3 (Mild) indicates fine texture changes with subtly accentuated skin lines, a score of 4 - 6 (Moderate) indicates distinct papular elastosis (\[indvidual papules with yellow translucency under direct lighting\] and dyschromia and a score of 7 - 9 (Severe) indicates multipapular and confluent elastosis \[thickened yellow and pallid\] approaching or consistent with cutis rhomboidalis. A lower class and a lower score means a better outcome.

Overall Acne Scar Improvement Assessed by the Global Aesthetic Improvement Scale (GAIS) at 12 Weeks Post-Final Treatment

时间窗: 12 Weeks Post-Final Treatment

Evaluate the efficacy of overall facial acne scar improvement assessed live by the Investigator and a subject assessment of facial appearance including the Global Aesthetic Improvement Scale (GAIS). The Global Aesthetic Improvement Scale is a seven-grade subjective test. Three independent evaluators evaluated before and after photographs and graded them for change. Possible responses were (3) Very Much Improved, (2) Much Improved, (1) Improved, (0) No Change, (-1) Worse, (-2) Much Worse, and (-3) Very Much Worse. For reporting of outcomes, the higher the GAIS value, the greater the improvement (Range -3 to 3).

次要结局

  • Subject Scale - Wong Baker FACES Pain Scale(12 Weeks Post-Final Treatment)
  • Subject Scale - 5 Point Scale for Treatment Tolerability(8 Weeks Post-Final Treatment)
  • Number of Participants With Treatment-Related Adverse Events(Up to 12 Weeks Post-Treatment)
  • Subject Satisfaction(6 and 12 Weeks Post- Final Treatment)

研究者

发起方
Venus Concept
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验